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CORRELATION BETWEEN THE LEVELS OF SURVIVIN AND 
SURVIVIN PROMOTER-DRIVEN GENE EXPRESSION IN CANCER 
AND NON-CANCER CELLS 
 
KRYSTYNA KONOPKA*, CHRISTOPHER SPAIN, ALLISON YEN, 
NATHAN OVERLID, SENAIT GEBREMEDHIN and NEJAT DÜZGÜNEŞ 
Department of Microbiology, University of the Pacific, Arthur A. Dugoni 
School of Dentistry, San Francisco, CA 94115, USA 
 
 
Abstract: Survivin, a member of the inhibitor of apoptosis (IAP) protein family, 
is associated with malignant transformation and is over-expressed in most 
human tumors. Using lipoplex-mediated transfection, we evaluated the activity 
of the reporter enzyme, luciferase, expressed from plasmids encoding the 
enzyme under the control of either the cytomegalovirus (CMV) or survivin 
promoters, in tumor- and non-tumor-derived human and murine cells. We also 
examined whether there is a correlation between the survivin promoter-driven 
expression of luciferase and the level of endogenous survivin. Human cancer 
cells (HeLa, KB, HSC-3, H357, H376, H413), oral keratinocytes, GMSM-K, 
and chemically immortalized human mammary cells, 184A-1, were transfected 
with Metafectene at 2 µl/1 µg DNA. Murine squamous cell carcinoma cells, 
SCCVII, mouse embryonic fibroblasts, NIH-3T3, and murine immortalized 
mammary cells, NMuMG, were transfected with Metafectene PRO at 2 µl/1 µg 
DNA. The expression of luciferase was driven by the CMV promoter 
(pCMV.Luc), the human survivin promoter (pSRVN.Luc-1430), or the murine 
survivin promoters (pSRVN.Luc-1342 and pSRVN.Luc-194). Luciferase 
activity was measured, using the Luciferase Assay System and expressed as 
relative light units (RLU) per ml of cell lysate or per mg of protein. The level of 
survivin in the lysates of human cells was determined by ELISA and expressed 
as ng survivin/mg protein. In all cell lines, significantly higher luciferase activity 
was driven by the CMV promoter than by survivin promoters. The expression of 




luciferase driven by the CMV and survivin promoters in murine cells was much 
higher than that in human cells. The cells displayed very different 
susceptibilities to transfection; nevertheless, high CMV-driven luciferase 
activity appeared to correlate with high survivin-promoter driven luciferase 
expression. The survivin concentration in lysates of cancer cells ranged from  
5.8 ± 2.3 to 24.3 ± 2.9 ng/mg protein (mean, 13.7 ng/mg). Surprisingly, elevated 
survivin protein was determined in lysates of non-tumor-derived cells. Survivin 
levels for GMSM-K and 184A-1 cells, were 16.7 ± 8.7 and 13.5 ± 6.2 ng/mg 
protein, respectively. The expression of endogenous survivin did not correlate 
with the level of survivin promoter-driven transgene activity in the same cells. 
The expression of survivin by non-tumorigenic, transformed cell lines may be 
necessary for their proliferative activity. The level of survivin promoter-driven 
gene expression achieved via liposomal vectors in OSCC cells was too low to be 
useful in cancer-cell specific gene therapy. 
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Carcinogenesis is a multi-factorial process involving the activation of oncogenes 
and the inactivation of tumor suppressor genes. Most human tumors are 
characterized by an imbalance of regulatory mechanisms controlling the cell 
cycle, the cell death/cell viability balance, and apoptosis [1, 2]. Apoptosis has 
become an important tool in developing new cancer strategies. In addition to 
pro- and anti-apoptotic Bcl-2 molecules, a second family of inhibitors of 
apoptosis (IAP) has been identified recently [3]. Survivin, a 16.5 kDa protein 
also known as baculoviral IAP repeat-containing protein 5 (BIRC5), represents  
a bi-functional IAP involved in the regulation of cell division at the G2/M phase 
and in the inhibition of apoptosis. Expressed at mitosis in a cell cycle-dependent 
manner and physically associated with the mitotic apparatus, survivin is essential 
for completion of various stages of cell division via regulation of microtubule 
dynamics and stability [4-7]. Survivin suppresses apoptosis by interfering with 
caspase-9 processing, the upstream initiation of the intrinsic (mitochondrial) 
pathway of apoptosis [8].  
Unlike other members of the Bcl-2 and IAP families, survivin has a unique 
expression profile. It is strongly upregulated in embryonic and fetal organs, but 
is essentially undetectable in most terminally differentiated normal tissues  
[9, 10], with the exception of thymocytes, CD34+ bone marrow-derived stem 
cells, and intestinal basal crypt epithelial cells [11]. A high re-expression of 
survivin has been shown in human tumors of lung, breast, colon, stomach, 
esophagus, pancreas, liver, uterus, ovaries, large cell non-Hodgkin’s lymphoma, 
leukemias, neuroblastoma, pheochromocytoma, soft-tissue sarcomas, gliomas, 
melanoma, and non-melanoma skin cancers [12, 13]. 
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Survivin is expressed in approx. 60-90% of oral squamous cell carcinomas 
(OSCCs) [14-18]. The cancer-specific expression of survivin makes it  
(i) a useful diagnostic marker of oral cancer [14] and (ii) a potential target for 
cancer treatment such as gene therapy [18-21]. The expression of survivin is an 
early event during oral carcinogenesis and may be useful for the identification of 
pre-cancerous lesions at higher risk of progression into invasive carcinoma  
[14, 15, 17]. Most OSCCs develop in the presence of clinical pre-malignant 
lesions [22]. Erythroplasias and dysplastic leukoplakias are the most common 
potentially malignant lesions, and about half of OSCCs exhibit associated 
leukoplakia [23]. Worldwide, OSCC is the most frequent malignant tumor of the 
oral cavity, and the sixth most common cancer in humans [24]. The high 
expression of survivin is associated with the more aggressive and invasive 
phenotype of OSCC [18, 25, 26]. Fifty two per cent of positively diagnosed 
patients have a mean survival time of only five years [27], a statistic that has not 
changed appreciably over the past 20 years. Even when the best combination of 
surgical and non-surgical treatments is used, more than 50% patients with OSCC 
will be affected by relapse, either locally, in regional lymph nodes, or at a distant 
site [24, 28].  
Gene therapy, which represents a new approach to the treatment of cancer, is 
based on the hypothesis that specific genes can be introduced into tumor cells to 
mediate a direct or indirect anti-tumor effect. Recently, several pre-clinical 
studies have shown promising results of gene therapy for the treatment of 
OSCC. Due to its frequent genetic mutations and accessibility for intra-tumor 
injection, OSCC is an especially appropriate target for gene therapy [29-31]. 
Most gene therapy approaches use non-specific strong prokaryotic promoters 
(CMV and SV40) that can be expressed at high levels in normal cells, 
potentially contributing to toxicity. An alternative approach would be to utilize 
tissue- or tumor-specific promoters to restrict the therapeutic gene expression to 
cancer cells [32, 33]. Since the survivin gene has essentially no transcriptional 
expression in normal tissues, the survivin promoter could be employed to 
enhance the specificity of therapeutic gene expression in OSCC cells.  
Here, using lipoplex-mediated transfection we evaluated the survivin- and the 
CMV promoter-driven expression of luciferase in human OSCC cell lines and 
SCCVII murine squamous carcinoma cells. The main purpose of our study was 
to compare (in the same cells) survivin expression driven by chromosomal 
survivin promoters (endogenous survivin) with survivin expression from 
plasmids driven by recombinant survivin promoter (exogeneous survivin) 
delivered by non-viral vectors. Non-tumor derived human and murine cells were 
also included in the study. To assess whether the survivin promoter-driven 
luciferase expression is correlated to the level of survivin, we measured survivin 
using ELISA in the lysates of cells that were used in transfection experiments. 
To our knowledge, this is the first study that compares the survivin promoter-
driven expression of a reporter gene with the survivin protein levels measured by 
a quantitative assay. The murine cell lines were included in our study because 




we are interested in establishing an efficient, tumor-specific non-viral gene 
delivery system for the treatment of OSCCs in immunocompetent C3H/HeJ 
mice. This orthotopic murine model for OSCC involves the injection of SCCVII 
murine squamous cell carcinoma cells in the floor of the mouth [34, 35]. Some 
of our results have been presented earlier in preliminary form [36, 37].  
 
MATERIALS AND METHODS 
 
Materials 
MetafecteneTM and Metafectene PROTM, polycationic liposomal transfection 
reagents, containing a polyamine-lipid and dioleoyl phosphatidylethanolamine 
(DOPE), were purchased from Biontex Laboratories GmbH (Munich, Germany). 
This new class of transfection reagents has been developed based on the 
Repulsive Membrane Acidolysis (RMA) technology that uses the acidic 
environment of the late endosomes to weaken the membrane structure of the 
lipoplexes. This is achieved by a protonable basic position near the lipophilic 
part of the cationic lipids. Repulsive forces among the positively charged 
lipophilic parts of the lipids then ease the disruption of the endosomal membrane 
and the release of the genetic material. Alamar Blue dye (alamarBlueTM) was 
purchased from Biosource International, Inc. (Camarillo, CA). The penicillin, 
streptomycin and L-glutamine solutions were obtained from the University of 
California San Francisco (UCSF) Cell Culture Facility (San Francisco, CA). 
 
Plasmids 
The plasmid pCMV.Luc (VR-1216; a gift of Dr. P. Felgner (Vical, San Diego, 
CA)) encoding luciferase was used for evaluating transfection efficiency under 
the control of the CMV promoter. The plasmid pSRVN.Luc-1430, encoding 
luciferase under the control of the human survivin promoter, which contains the 
proximal 1430 nt upstream of the survivin transcription start site [38-40], and 
two plasmids encoding luciferase under the control of the murine survivin 
promoter, pSRVN.Luc-1342 and pSRVN.Luc-194, were used for evaluating the 
survivin promoter-driven expression of luciferase. The promoter sequences in 
pSRVN.Luc-1342 are close to the full length of the survivin promoter, while 
pSRVN.Luc-194 is truncated at 194 bp upstream of the transcription initiation 
site [4]. Sharing an overall 84% identity with the human survivin, the mouse 
survivin protein contains a structurally unique single baculovirus iap repeat 
(BIR), that is required for apoptosis inhibition, and a –COOH-terminus coiled 
domain instead of a RING finger [4]. The plasmids were obtained from Dr. F. Li 
(Roswell Park Cancer Institute, Buffalo, NY) and propagated by Qiagen Inc. 
(Fargo, ND) (endotoxin level: <100 EU per mg). 
 
Cell culture  
Five human OSCC cell lines, two human non-tumor cell lines, one murine SCC 
cell line, and two murine non-tumor-derived cell lines were utilized in this study. 
Two cell lines derived from SCC of the tongue, HSC-3 [41] and H-357 [42], 
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were provided by Dr. R. Kramer (UCSF). H-413 cells, derived from SCC of the 
buccal mucosa, and H-376 cells, derived from SCC of the floor of the mouth 
[42], were obtained from Dr. R. Jordan (UCSF). The human oropharyngeal 
epidermoid carcinoma KB cell line [43] was obtained from the UCSF Cell 
Culture Facility. Non-tumor-derived human oral keratinocytes, GMSM-K, [44] 
were provided by Dr. V.A. Murrah (University of North Carolina at Chapel 
Hill). The 184A1 immortalized mammary epithelial cell line was derived from 
primary mammary cultures obtained from normal breast tissue and transformed 
in vitro with benzo(a)pyrene [45]. This cell line is not malignant when injected 
into nude mice, and it has a nearly complete diploid karyotype [46]. The cells 
were purchased from ATCC (CRL-8798, Rockville, MD). SCCVII, an 
aggressive murine cell line was established from the squamous cell carcinoma 
that developed spontaneously in C3H/HeJ mice and has been propagated 
subsequently in vitro [47]. For our studies, SCCVII cells were provided by Drs. 
D. Li and B. O’Malley (University of Pennsylvania, Philadelphia, PA). The 
NIH-3T3 mouse embryonic fibroblast continuous cell line, developed from  
a NIH Swiss mouse embryo [48], was obtained from the UCSF Cell Culture 
Facility. The NMuMG mouse mammary gland epithelial cell line, established 
through spontaneous immortalization of normal mammary epithelial cells of 
NAMRU mice [49], was purchased from ATCC (CRL-1636). The cells produce 
benign cystadenomas when inoculated into isogenic mice. The human cervical 
epithelial cancer cell line HeLa (ATCC) was also included in our study. These 
epithelial cells are readily transfectable and are used frequently in transfection 
assays. 
All cell lines were maintained at 37°C in CO2 (5%) incubators. Unless otherwise 
noted, all media were purchased from the UCSF Cell Culture Facility. HSC-3, 
H-357, H-376, HeLa, SCCVII and NIH-3T3 were cultured in Dulbecco’s 
modified Eagle’s MEM supplemented with 10% (v/v) heat-inactivated fetal 
bovine serum (FBS), penicillin (100 U/ml), streptomycin (100 µg/ml) and  
L-glutamine (4 mM) (DMEM/10). H-413 cells were maintained in DMEM/10 
supplemented with Ham’s Nutrient Mixture F12. KB cells were cultured in 
Minimal Essential Medium (MEM) supplemented with 10% FBS. GMSM-K 
cells were propagated in keratinocyte-SFM medium supplemented with human 
recombinant epidermal growth factor and bovine pituitary extract (Invitrogen, 
Carlsbad, CA). 184A-1 cells were maintained in serum-free Mammary Epithelial 
Base Medium (MEBM) supplemented with 5 ng/ml transferrin and 1 ng/ml 
cholera toxin (Clonetics, Walkersville, MD). NMuMG cells were grown in 
ATCC modified DMEM/10 medium containing 4.5 g/l glucose and 1.5 g/l 
sodium bicarbonate, supplemented with 0.01 mg/ml bovine insulin and 10% FBS.  
 
Transfection protocol 
Cells were seeded in either 48-well or 24-well plates at a density between  
1.0-3.0 x 105 cells per well in 1 ml of appropriate medium one day before the 
experiment, and used at approximately 60-80% confluence. The cells were pre-




washed with serum-free medium and then covered with 0.4 ml of the same 
medium. Lipid-DNA complexes were prepared by mixing Metafectene or 
Metafectene PRO with 100 µl of serum-free medium, followed by the addition 
of plasmid DNA. The mixture was incubated for 15 min at room temperature 
after the addition of the transfection reagent, and another 15 min after addition 
of DNA. Lipid/DNA complexes were added in a volume of 0.1 ml per well, the 
cells were incubated for 4 h at 37°C, and then 0.5 ml of serum-containing 
medium was added. The optimal ratio of Metafectene and Metafectene PRO to 
DNA was determined as described previously [50]. Luciferase activity was 
assayed 48 h after transfection, using the Luciferase Assay System (Promega, 
Madison, WI), and a TD-20/20 luminometer (Turner Designs, Sunnyvale, CA). 
The data were expressed as relative lights units (RLU) per ml of cell lysate or 
per mg protein. These values are designated “transfection activity”. The protein 
content of the lysates was measured by the DC Protein Assay reagent (Bio-Rad, 
Hercules, CA) using bovine serum albumin Fraction V (Sigma) as the standard. 
The data obtained with the plasmids expressing luciferase under the control of 
the survivin promoter were normalized to the CMV promoter-driven expression. 
This comparison was used to account for the potentially different levels of 
transgene expression achieved in the different cell lines employed. To normalize 
transfection efficiency, we also used the Dual-Luciferase Reporter Assay System 
according to the manufacturer’s protocol (Promega). In this system, the plasmid 
pRL-SV-40 that contains the Renilla luciferase gene under the control of the  
SV-40 promoter is co-transfected as an internal control. However, the highly 
variable Renilla luciferase expression in oral cancer cells made it difficult to use 
this system to normalize the survivin promoter-driven luciferase values.  
 
Survivin ELISA 
The level of survivin in cell lysates was measured using the human Total 
Survivin TiterZyme Enzyme Immunometric Assay (EIA) kit developed recently 
by Assay Designs Inc. (Ann Arbor, MI). This is a complete kit for the 
quantitative determination of human survivin in serum, plasma, urine, and cell 
lysates. Two-fold serial dilutions of recombinant human survivin, at  
a concentration range of 31.25-1000 pg/ml, were used as standards. The cell 
lysates were analyzed in duplicate, diluted 1:60 and 1:120, respectively. The 
standards and samples (100 µl/well) were incubated in plates pre-coated with  
a monoclonal antibody to survivin for 1 h at room temperature on a plate shaker 
at ~500 rpm. Subsequently, the plates were washed 5 times and 100 µl of rabbit 
polyclonal anti-survivin antibody was added to each well. The plates were 
incubated and washed as before, and 100 µl of a goat anti-rabbit IgG conjugated 
to horseradish peroxidase was added to each well. The plates were incubated for 
30 min at room temperature, washed again and 100 µl of tetramethylbenzidine 
(TMB) substrate solution was added to each well. After 30 minutes, the reaction 
was stopped with 100 µl of 1 M HCl. The plate was read at 450 nm and 570 nm. 
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The concentration of survivin in cell lysates was determined by interpolation 
from a standard curve. 
 
Cell viability assay  
Cell morphology was evaluated by inverted phase contrast microscopy at 25x 
magnification. The number of viable cells used for the experiments was 
determined by Trypan Blue exclusion. Cell viability was quantified by  
a modified Alamar Blue assay [51, 52]. Cell viability (as a percentage of mock-
treated control cells) was calculated according to the formula [(A570 - A600) of 
test cells] x 100 / [(A570 - A600) of control cells].  
 
Statistical analysis 
Data were compared for statistical significance by the unpaired Student's t-test, 
using StatView software (BrainPower, Inc., Calabasas, CA). A probability value 




Transgene expression in human cells driven by the survivin and CMV 
promoters 
The ratios of transfection reagent/DNA (v/w) were selected based on the 
manufacturer’s recommendations. At first, the transfection efficiency of 
Metafectene and Metafectene PRO was optimized in HeLa, HSC-3 and H413 
cells as described previously [53]. Metafectene and Metafectene PRO were 
complexed with the pCMV.Luc plasmid at reagent:DNA ratios of 1 µl:0.5 µg,  
2 µl:0.5 µg, 2 µl:1 µg or 4 µl:1 µg DNA. The optimal conditions for all three 
cell lines were 2 µl:1 µg DNA per well (Fig. 1A and Fig. 2A) and subsequent 
experiments were performed under these conditions. When compared to mock-
transfected controls, the cytotoxic effect of the Metafectene- and Metafectene 
PRO-mediated transfection was very low (Fig. 1B and Fig. 2B). At 4 µl:1 µg 
DNA, Metafectene-mediated transfection was toxic in HSC-3 cells (P<0.01), 
while Metafectene PRO-mediated transfection was toxic in H413 cells (P<0.05).  
Metafectene was used at 2 µl:1 µg DNA (theoretical charge ratio of 3.68:1 (+/-)). 
To assess whether the activation of the survivin promoter is cancer-specific and 
to compare the cancer cell-specificity between the survivin promoter and the 
commonly used CMV promoter, tumor and non-tumor human cells were 
transfected with plasmids encoding luciferase under the control of either the 
human survivin promoter (pSRVN.Luc-1430) or the CMV promoter 
(pCMV.Luc) (Fig. 3A). A relatively high expression of luciferase activity driven 
by pSRVN.Luc-1430 was observed in HeLa cells (6,843 ± 2,607 RLU/ml), 
HSC-3 cells (1,720 ± 887 RLU/ml) and H376 cells (394 ± 202 RLU/ml). The 
two tumor cell lines, H357 and H413, did not display notably greater expression 
than that in the non-tumor-derived GMSM-K and 184A-1 cells. The activity of 
luciferase in H357 and H413 cells was not significantly different from that in 
 





Fig. 1. Transfection activity and cytotoxicity of Metafectene under different conditions in 
HeLa, HSC-3 and H413 cells. A – Luciferase activity determined 48 h after transfection 
and expressed as relative light units (RLU) per ml of cell lysate. B – Cell viability 
measured by the Alamar Blue assay. Results are expressed as a percentage of mock-
transfected controls. Data represent the mean ± S.D. obtained from triplicate wells.  
 
GMSM-K cells (P<0.375). In all human cell lines, significantly higher luciferase  
activity was driven by the CMV promoter than by the human survivin promoter 
(Fig. 3). The highest expression of luciferase was observed in HeLa cells 
(341,900 ± 71,230 RLU/ml). The five OSCC cell lines displayed very different 
susceptibilities to transfection. The relatively high luciferase activities detected 
in H376, KB and HSC-3 cells were 131,683 ± 2,248, 62,560 ± 15,124 and 
33,466 ± 2,953 RLU/ml, respectively. The expression of luciferase was much 
lower in H357 and H413 cells, 2,039 ± 856 and 2,048 ± 1,080, respectively. The 
results may be related to the less efficient internalization of lipoplexes by these 
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cells, since the survivin promoter-driven luciferase expression was also very low 
(~20 ± 10 RLU/ml). Overall the survivin promoter-driven luciferase expression 
was a small percentage of that driven by the CMV promoter. Notable among the 
cells were HSC-3 and HeLa for which the percentage were 5.1 and 2.0, 
respectively (Fig. 3B). The cells displayed very different susceptibilities to 
transfection; nevertheless, high CMV-driven luciferase activity appeared to 
correlate with high survivin-promoter driven luciferase expression. 
 
 
Fig. 2. Transfection activity and cytotoxicity of Metafectene PRO under different 
conditions in HeLa, HSC-3 and H413 cells. A – Luciferase activity determined 48 h after 
transfection and expressed as relative light units (RLU) per ml of cell lysate. B – Cell 
viability measured by the Alamar Blue assay. Results are expressed as a percentage of 
mock-transfected controls. Data represent the mean ± S.D. obtained from triplicate wells.  





Fig. 3. The expression of luciferase by tumor and non-tumor human cells transfected with 
Metafectene-complexed plasmids encoding the enzyme under the control of either the 
human survivin promoter (pSRVN.Luc-1430) or the CMV promoter (pCMV.Luc). The 
cells were transfected with Metafectene at 2 µl/1 µg DNA. Results: A – as relative light 
units per ml (RLU/ml), B – as a percentage of CMV promoter-driven luciferase activity 
[(RLU induced by the survivin promoter/RLU induced by the CMV promoter) x 100%]. 
Values represent means ± S.D. and are representative of three separate experiments 
performed in triplicate. For details see Materials and Methods. 
 
Transgene expression in murine cells driven by the survivin and CMV 
promoters 
 
We next investigated the activity of luciferase expressed from plasmids 
encoding the enzyme under the control of two murine survivin promoters 
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(pSRVN.Luc-1342 and pSRVN.Luc-194) and the CMV promoter. We used  
a murine squamous cell carcinoma cell line, SCCVII, and two non-tumor-
derived murine cell lines, 3T3-NIH and NMuMG (Tab. 1). SCCVII cells are 
employed in the generation of OSCC tumors in an oral cancer model in 
C3H/HeJ mice [34, 35]. Transfection efficiency of a novel polycationic 
transfection reagent, Metafectene PRO, was optimized in HeLa, SCCVII and 
NIH-3T3 cells. Metafectene PRO was used at 1 µl:0.5 µg, 2 µl:0.5 µg, 2 µl:1 µg, 
and 4 µl:1 µg DNA with the pCMV.Luc plasmid. The highest expression of 
luciferase was obtained with 2 µl Metafectene PRO:1 µg DNA [37], and the 
subsequent experiments were performed under this condition. When compared 
to mock-transfected controls, Metafectene PRO-mediated transfection with 
pCMV.Luc plasmid did not result in the reduction of total amounts of 
extractable cellular protein in lysates of HeLa, SCCVII and NIH-3T3 cells (data 
not shown). 
The expression of luciferase driven by the CMV and survivin promoters in 
murine cells was much higher than that in human cells (Tab. 1). Significantly 
higher levels of luciferase activity were driven by the CMV promoter than by 
survivin promoters. SCCVII cells were readily transfectable [53]. The CMV 
promoter-driven, Metafectene PRO-mediated expression of luciferase in 
 
Tab. 1. The expression of luciferase by SCCVII, 3T3-NIH and NMuMG cells transfected 
with Metafectene PRO-complexed with plasmids encoding the enzyme under the control 
of the murine survivin promoter (pSRVN.Luc-1342 and pSRVN.Luc-194) and the CMV 
promoter (pCMV.Luc). 
 
Murine cells Plasmid Luciferase activity (RLU/ml) % RLU of CMV 
SCCVII  pCMV.Luc   10,733,667 ± 2,983,447 100.00 
 pSRVN.Luc-1342               13,798 ± 670     0.13 
 pSRVN.Luc-194     9,457 ± 1,201     0.09 
NIH-3T3 pCMV.Luc         1,378,511 ± 20,513 100.00 
 pSRVN.Luc-1342    7,069 ± 1,013     0.51 
 pSRVN.Luc-194 2,095 ± 319     0.15 
NMuMG pCMV.Luc    5,257,333 ± 1,549,978 100.00 
 pSRVN.Luc-1342    27,048 ± 13,555     0.51 
 pSRVN.Luc-194 18,638 ± 1,662     0.35 
 
The cells were transfected with Metafectene PRO at 2 µl/1 µg DNA. Results are shown as relative 
light units per ml (RLU/ml) or as a percentage of CMV promoter-driven luciferase activity [(RLU 
induced by the survivin promoter/RLU induced by the CMV promoter) x 100%] Values represent 
means ± S.D. and are representative of two separate experiments performed in triplicate. For 
details see Materials and Methods. 
 
SCCVII cells was very high. The average value of luciferase activity (RLU/ml) 
was 10.7 x 106 ± 3.0 x 106, but in some experiments the values were even higher, 
in the range 20-36 x 106 RLU/ml. The high efficiency of transfection with the 




pCMV.Luc plasmid was also observed in non-tumor-derived murine cells, NIH-3T3 
and NMuMG (Tab. 1). The murine survivin promoters demonstrated greater 
transgene expression in murine cells than that observed in human cells with the 
human survivin promoter. The lowest expression of luciferase was found in the 
non-tumorigenic NIH-3T3 embryonic fibroblast cell line. Nevertheless, these 
values were still much higher than that obtained in human OSCC cells (Fig. 3A).  
The full survivin promoter (pSRVN.Luc-1342) produced consistently higher 
activity of luciferase compared to the truncated promoter (pSRVN.Luc-194). 
The highest expression of luciferase driven by the murine survivin promoters 
was observed in NMuMG cells (Tab. 1). These epithelial cells derived from the 
mammary gland, induce benign cystadenomas in isogenic mice and may have  
a potential for overexpression of survivin. In addition, this apparently normal 
cell population is capable to spontaneous malignant transformation in culture [54]. 
 
Correlation of the survivin promoter-driven luciferase expression with the 
survivin protein levels measured by the human survivin ELISA  
 
All of the cancer cell lines derived from the epithelium were positive for 
survivin measured by ELISA (Tab. 2). The survivin protein concentration in cell 
lysates of cancer cells ranged from 5.8 ± 2.3 to 24.3 ± 2.9 ng per mg of protein 
(mean, 13.7 ng/mg). In H357 and H376 cells, in which the level of endogenous 
survivin was the lowest among the cells investigated, the survivin promoter-
driven luciferase expression was also quite low. However, a comparison 
between HSC-3 and H376 cells indicates that the normalized (with respect to 
 
Tab. 2. Metafectene-mediated expression of luciferase driven by the CMV promoter 
(pCMV.Luc) and the human survivin promoter (pSRVN.Luc-1430), and the levels of 
survivin protein in cell lysates of tumor and non-tumor human cells.  
 
Cells 
Luciferase activity (RLU/mg protein)a Survivin 
(ng/mg protein)b pCMV.Luc pSRVN.Luc-1430
HeLa  268,677 ± 15,674 4,447 ± 2020 24.3 ± 2.9 
KB    57,561 ± 15,231   192 ± 116 21.5 ± 0.8 
HSC-3    52,551 ± 24,006       2,633 ± 919 12.0 ± 2.9 
H413 1,024 ± 540  25 ± 16 12.6 ± 0.9 
H357 1,731 ± 769  4 ± 2  6.2 ± 1.4 
H376 61,275 ± 4,322  71 ± 38  5.8 ± 2.3 
GMSM-K 1,721 ± 447  6 ± 2 16.7 ± 8.7 
184A-1 4,031 ± 631  6 ± 6 13.5 ± 6.2 
 
a The cells were transfected with Metafectene at 2 µl/1 µg DNA. Values represent means ± S.D. 
and are representative of three separate experiments performed in triplicate. b The level of survivin 
in cell lysates was measured using the human Total Survivin TiterZyme Enzyme Immunometric 
Assay. Survivin levels were normalized to total protein. Values represent means ± S.D. and are 
representative of two independent determinations. For details see Materials and Methods. 
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CMV-driven expression) survivin promoter-driven expression was 43-fold 
higher in HSC-3 cells, while the level of endogenous survivin was only 2-fold 
higher (Tab. 2). CMV-driven luciferase expression in HeLa cervical carcinoma 
cells was significantly higher that that in the oral cancer cells. However, the 
normalized survivin promoter-driven expression in HeLa cells (0.02) was lower 
than that in HSC-3 cells (0.05) (Fig. 3B), while the level of endogenous survivin 
was higher by a factor of 2 (Tab. 2). Thus, the efficiency of gene expression 
from transfected plasmid does not correlate with endogenous levels of survivin. 
Interestingly, elevated survivin protein was determined in lysates of non-tumor-
derived human cells. The values of ELISA survivin for GMSM-K oral 
keratinocytes and 184A-1 chemically immortalized, normal human mammary 
epithelial cells, were 16.7 ± 8.7 and 13.5 ± 6.2 ng/mg protein, respectively. It 
could be hypothesized that these immortal but not tumorigenic, transformed cell 
lines express all proteins, including survivin, which are necessary for 
proliferative activity. The high level of endogenous survivin did not correlate 




Most viral and non-viral gene therapy approaches use non-specific viral 
promoters (CMV and SV40) that can be expressed at high levels even in non-
tumor cells, potentially contributing to toxicity. An alternative approach involves 
transcriptional targeting that utilizes promoters activated preferentially in tumor 
cells, but not in normal cells. An ideal tumor-specific promoter (TSP) exhibits 
selective high activity in tumor cells (a “tumor on” phenotype). To diminish 
hepatotoxicity after systemic delivery, candidate promoters should display low 
activity in the liver (a “liver off” phenotype). Many TSPs have been explored for 
specific cancers, such as the prostate-specific antigen (PSA) for prostate cancer 
and the a-fetoprotein (AFP) promoter for hepatocarcinoma [55]. Recently,  
a novel TSP, the survivin promoter, that exhibits a tumor on/liver off phenotype 
in a wide range of tumors, has been described [12, 13]. To our knowledge, this is 
the first study that examined the survivin promoter-driven gene expression in 
oral cancer cells. These relatively comparable cells derived from OSCC tumors, 
displayed very different susceptibilities to transfection both with the survivin 
and the CMV promoter. In all cells, a significantly lower luciferase activity was 
driven by the survivin promoters than by the CMV promoter.  
There are only a few reports describing the survivin promoter-driven gene 
expression mediated by liposomal vectors. Both the survivin promoter activities 
and the comparisons of their efficacies with that of viral promoters (CMV and 
SV40) have produced variable results. Although, the survivin promoter was 
usually more active in tumor cells than in non-tumor-derived cells, the tumor 
cells displayed very different susceptibilities to transfection [19, 21, 39, 56]. The 
activity of luciferase driven by the survivin promoter in cancer cells transfected 
with DOTAP:Chol liposomes was 10 to 40% of that driven by the CMV 




promoter [19]. Conflicting results were also reported for the survivin vs. SV40 
promoter activity in different cancer cells [19, 56].  
Several groups have constructed conditionally replicating adenoviruses 
(CRAds), in which the survivin promoter regulates expression of the adenoviral 
early region 1A (E1A) gene [40, 55-58]. The transcriptional activity of the 
survivin-responsive CRAd in cancer cells was in the range of 1-16% of that 
driven by the CMV promoter [40]. To increase the transduction efficiency of 
survivin-responsive CRAds, Zhu et al. [55] incorporated a capsid modification 
(RGD or F5/3) into the adenovirus fiber region. The activity of luciferase driven 
by seven TSPs (Cox-2, CXCR4, EGP-2, HRP, SLPI, MsLn, and survivin) was 
evaluated in four human mesothelioma cell lines. The mean activity of luciferase 
for the survivin promoter was 8.9% of that for the CMV promoter. The 
adenoviral gene transduction efficiency was evaluated in cancer cells infected 
with E1-deleted replication-defective Ad.RSV-LacZ, Ad.CMV-LacZ and 
Ad.Surv-LacZ [58]. β-galactosidase activity depended both on cell type and the 
promoter. Ad.Surv-LacZ provided strong transcriptional activation in these 
cancer cells that display high β-gal activity after infection with Ad.CMV-LacZ.  
In summary, the cancer-specificity of the survivin promoter appears greater than 
that of the CMV, SV40, and RSV promoters, but variations both in experimental 
conditions, and in presentations of the results (relative vs. absolute data), as well 
as extensive variability in the efficiency of transfection/transduction in different 
cancer cells make direct comparisons very difficult. There may be nucleotide 
sequence variation between survivin promoter clones isolated from different 
tumor cell lines. To evaluate this, we queried the Entrez Nucleotide Sequence 
Database producing six clones for the survivin/BIRC5 promoter. These clones 
were analyzed using BLAST sequence alignment producing no variation in 
sequence across the six clones. A few studies have investigated the 
survivin/BIRC5 promoter polymorphism. Xu et al. [59] described three 
mutations of the survivin/BIRC5 promoter. Mutations at the -235bp and -241bp 
sites were seen infrequently in the screened cell lines, which included tumor- 
and non-tumor-derived cells. In contrast, the C to G transition at -31bp has been 
observed frequently in cancer cells but not in normal cells tested. This finding 
was supported by Jang et al. [60], who described the polymorphism at -31bp as 
strongly correlating with the presence of lung cancer. Borbely et al. [61] refutes 
this finding indicating that the -31bp polymorphism does not strongly correlate 
with cervical cancer. This discrepancy in reporting indicates that the issue of 
polymorphisms in the survivin/BIRC5 promoter warrants continued 
investigation.  
In an attempt to estimate whether the survivin promoter-driven luciferase 
expression is correlated to the level of endogenous survivin, we measured the 
amount of survivin protein in the lysates of cells that were used in transfection 
experiments. The survivin concentration in lysates of oral cancer cells ranged 
from 5.8 ± 2.3 to 21.5 ± 0.8 ng/mg protein (Tab. 2). These values are 
comparable to the levels of survivin (4.1 to 32.6 ng/mg protein) reported for 
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epithelial cell lines derived from prostate, bladder and breast tumors [62]. 
Survivin was undetectable in primary lymphocytes and in 8 of 10 tissue samples 
of non-tumor origin. Relatively low survivin content was found in samples taken 
from normal spleen and stomach [62]. The latter authors assume that these 
proliferative active tissues express all proteins that are necessary for correct 
chromosomal segregation. In our study, relatively high values of survivin were 
found in GMSM-K oral keratinocytes and 184A-1 human mammary epithelial 
cells. Our observation suggests a correlation between the expression of survivin 
and the proliferative activity of each cell type. Generally, cell lines that are not 
cancerous in origin must undergo some form of chemical immortalization to be 
cultured. We feel that this immortalization process may impact survivin 
production, making tumor/normal-tissue comparison by ELISA unrepresentative 
of wild-type conditions. Furthermore, ELISA data obtained from cultured cell 
lines will represent only the tissues that can be cultured. A low level of survivin 
mRNA was detected in normal WI-38 human fibroblasts and primary human 
osteoblasts [58]. By Western blot analysis, an intense survivin band was detected 
in transformed rat (ROSE-Tag, NuTu19, and NuTu26) and murine (IG10 and 
IF5) ovarian cell lines, but only a faint band was detected in early-passage 
normal ROSE and MOSE cells. A faint survivin band was detected in non-
tumorigenic murine NIH-3T3 fibroblasts [19].  
The observation that endogenous survivin expression does not correlate with 
luciferase expression from the exogenous survivin promoter suggests that the 
efficiencies of the endogenous and exogenous promoters are different. The level 
of endogenous survivin reflects the relatively high efficiency with which the 
chromosomal promoter mediates gene expression. The efficiency of the 
exogenous survivin promoter on the plasmid, transfected via a non-viral vector, 
appears to be compromised by the entire transfection process. The luciferase 
activity is a function of transfection efficiency. The expression of a transfected 
gene can suffer interference at any point from cell entry to post-translational 
modifications. This creates an inherent inaccuracy when comparing luciferase 
activity in different cell lines without a control for transfectional and 
expressional efficiency. Preliminary experiments with fluorescent Metafectene 
showed low levels of cell-associated fluorescence in cell types that expressed 
low luciferase activity (N. Düzgüneş, C. Lavoroni-Doyle, S. Gebremedhin and 
K. Konopka, unpublished data). Survivin-driven luciferase expression in oral 
cancer cells is much lower as a percentage (≤ 5.1) of CMV-driven luciferase 
expression compared to other human cancer cells [21]. This observation is 
somewhat surprising in view of the fact that levels of endogenous survivin in 
oral cancer and other cancer cells are similar [62]. RT-PCR analyses showed that 
survivin mRNA is expressed in multiple cancer cells derived from a variety of 
tissue origins. The levels of survivin mRNA, however, varied widely among the 
different cancer cell lines, and not all cancer cells expressed a high level of 
survivin transcripts [9, 40, 58].  




The inability of the survivin promoter to drive high-level gene expression in oral 
cancer cells appears to preclude its potential use in gene therapy. The rationale 
for the different susceptibility to transfection observed with different cells may 
include differences in binding, endocytosis and intracellular transport of 
liposome-DNA complexes, as well as in transcription activity. The rationale for 
the differences observed in endogenous survivin expression in oral cancer cells 
may include polymorphisms in the survivin gene promoter and/or variations in 
transcriptional as well as post-transcriptional regulation mechanisms. Future 
studies to elucidate the nature of these factors and their effects on transfection 
may enable the development of more effective therapy strategies.  
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